Klara Pohl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Klara Pohl has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Hanna Zurl
Department of Urology Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Urology, Medical University of Graz, Graz, Austria
5 shared publications - Alexander Putnam Cole
Brigham and Women’s Hospital
4 shared publications - Daniel Stelzl
Department of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
4 shared publications - Quoc-Dien Trinh
Department of Urology, University of Pittsburgh, Pittsburgh, PA
4 shared publications - Stephan Korn
Department of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
4 shared publications - Zhiyu Qian
Department of Urology, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts USA
4 shared publications
Latest Publications
- 30 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-10
Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes
- 30 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-10
Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes
- Open Access
Association of Travel Burden with Definitive Prostate Cancer Treatment: A United States Registry Cohort Study
Purpose: Prostate cancer (PCa) mortality disparities are partly driven by unequal access to care. Transportation barriers may limit access to definitive treatment. We studied how driving travel time affects receipt of definitive PCa treatment. Materials and Methods: We conducted a cohort study of men with non-metastatic PCa (2000 - 2015; follow-up through 2018) across the metropolitan area cancer registries of seven US states. Travel burden was estimated using Google Maps isochrones representing driving time thresholds to reach the hospital appended to geomasked residential addresses. Outcomes were “no treatment, “ “radical surgery,” or “radiotherapy”. Covariate-adjusted multinomial logistic regression with interaction terms assessed modification by sociodemographic factors. Results: The study included 132,939 men, of whom 37.0% received no treatment, 41.0% underwent surgery, and 22.0% received radiotherapy. Longer driving time (≥90 min vs <30 min) was associated with higher radical prostatectomy (aOR: 1.07, 95% CI: 1.03, 1.12), but lower radiotherapy (0.72, 95% CI: 0.69 - 0.76). Subgroup analyses revealed higher surgery associated with longer driving times among those in nSES Q1 (aOR: 1.33, 95% CI: 1.21-1.45) vs Q5 (aOR: 0.94, 95% CI: 0.86-1.04), those in low (aOR: 1.16, 95% CI: 1.09-1.24) vs high (aOR: 1.03, 95% CI: 0.98-1.09) population density areas, and those with regional (aOR: 1.30, 95% CI: 1.14-1.48) vs localized (aOR: 1.05, 95% CI: 1.00 -1.09) disease. Longer driving time was mostly associated with lower odds of radiotherapy across sociodemographic subgroups. Conclusions: Higher travel burden was associated with lower radiotherapy receipt, but greater surgery use in deprived and rural patients, which warrants further investigation.
Open AccessAssociation of Travel Burden with Definitive Prostate Cancer Treatment: A United States Registry Cohort Study
Purpose: Prostate cancer (PCa) mortality disparities are partly driven by unequal access to care. Transportation barriers may limit access to definitive treatment. We studied how driving travel time affects receipt of definitive PCa treatment. Materials and Methods: We conducted a cohort study of men with non-metastatic PCa (2000 - 2015; follow-up through 2018) across the metropolitan area cancer registries of seven US states. Travel burden was estimated using Google Maps isochrones representing driving time thresholds to reach the hospital appended to geomasked residential addresses. Outcomes were “no treatment, “ “radical surgery,” or “radiotherapy”. Covariate-adjusted multinomial logistic regression with interaction terms assessed modification by sociodemographic factors. Results: The study included 132,939 men, of whom 37.0% received no treatment, 41.0% underwent surgery, and 22.0% received radiotherapy. Longer driving time (≥90 min vs <30 min) was associated with higher radical prostatectomy (aOR: 1.07, 95% CI: 1.03, 1.12), but lower radiotherapy (0.72, 95% CI: 0.69 - 0.76). Subgroup analyses revealed higher surgery associated with longer driving times among those in nSES Q1 (aOR: 1.33, 95% CI: 1.21-1.45) vs Q5 (aOR: 0.94, 95% CI: 0.86-1.04), those in low (aOR: 1.16, 95% CI: 1.09-1.24) vs high (aOR: 1.03, 95% CI: 0.98-1.09) population density areas, and those with regional (aOR: 1.30, 95% CI: 1.14-1.48) vs localized (aOR: 1.05, 95% CI: 1.00 -1.09) disease. Longer driving time was mostly associated with lower odds of radiotherapy across sociodemographic subgroups. Conclusions: Higher travel burden was associated with lower radiotherapy receipt, but greater surgery use in deprived and rural patients, which warrants further investigation.
- 9 September 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (4) , 1239-1247
Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970–2024)
Background With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored. In this study, we aim to analyze malpractice lawsuits related to prostate cancer ablative therapies using a national legal database. Methods In this retrospective study, we utilized the LexisNexis Database to analyze ablative therapy malpractice lawsuits between 1970 and 2024. We searched for keywords “ablative therapy” “focal therapy” “high-intensity focused ultrasound” “HIFU” “cryotherapy” “cryoablation” “laser” “irreversible electroporation” and “IRE” We excluded cases that did not involve ablative treatment of prostate cancer. We then reviewed cases for treatment method, allegation, claimed liabilities, verdict, and plaintiff award. Results We identified 180 lawsuits using the keywords provided, and 5 cases met inclusion criteria. All five lawsuits involved cryoablation for prostate cancer. The most common precipitating injury was rectal injury (3, 60%). Allegations included negligence (2, 25%), deviation from the standard of care (2, 25%), deliberate indifference (2, 25%), and failure to consent (2, 25%). Verdicts were predominantly favorable to defendants (4, 80%), and one case (20%) resulted in an unknown outcome. Conclusions Ablative therapy had a limited number of lawsuits, with outcomes favorable to surgeons and minimal financial payouts. As ablative therapy continues to gain popularity, urologists must practice proper surgical techniques, conduct thorough informed consent, and exercise excellent patient–provider communication to help minimize the occurrence and impact of litigations involving ablative therapy. These findings may help guide future patient risk counseling and support adjustments in malpractice insurance policies as the use of ablative therapies expands, while also informing physicians and hospital systems considering their adoption or expansion.
- 9 September 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (4) , 1239-1247
Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970–2024)
Background With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored. In this study, we aim to analyze malpractice lawsuits related to prostate cancer ablative therapies using a national legal database. Methods In this retrospective study, we utilized the LexisNexis Database to analyze ablative therapy malpractice lawsuits between 1970 and 2024. We searched for keywords “ablative therapy” “focal therapy” “high-intensity focused ultrasound” “HIFU” “cryotherapy” “cryoablation” “laser” “irreversible electroporation” and “IRE” We excluded cases that did not involve ablative treatment of prostate cancer. We then reviewed cases for treatment method, allegation, claimed liabilities, verdict, and plaintiff award. Results We identified 180 lawsuits using the keywords provided, and 5 cases met inclusion criteria. All five lawsuits involved cryoablation for prostate cancer. The most common precipitating injury was rectal injury (3, 60%). Allegations included negligence (2, 25%), deviation from the standard of care (2, 25%), deliberate indifference (2, 25%), and failure to consent (2, 25%). Verdicts were predominantly favorable to defendants (4, 80%), and one case (20%) resulted in an unknown outcome. Conclusions Ablative therapy had a limited number of lawsuits, with outcomes favorable to surgeons and minimal financial payouts. As ablative therapy continues to gain popularity, urologists must practice proper surgical techniques, conduct thorough informed consent, and exercise excellent patient–provider communication to help minimize the occurrence and impact of litigations involving ablative therapy. These findings may help guide future patient risk counseling and support adjustments in malpractice insurance policies as the use of ablative therapies expands, while also informing physicians and hospital systems considering their adoption or expansion.
- 27 June 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (1) , 214-222
Factors associated with mesorectal lymph node metastasis in prostate cancer patients
Purpose To evaluate radiological and pathological factors associated with mesorectal lymph node (MLN) metastases in prostate cancer patients, as detected by Prostate Specific Membrane Antigen (PSMA) imaging with Positron Emission Tomography/Computed Tomography (PET/CT). Methods In a retrospective case-control study of 135 prostate cancer patients who underwent PSMA PET/CT between January 2022 and October 2024, forty-five patients with positive mesorectal nodal uptake were matched 1:2 with control patients based on age and International Society of Urological Pathology (ISUP) grade. All patients had multiparametric prostate MR imaging and biopsy results available. We analyzed radiological features (PI-RADS scores, extraprostatic extension, seminal vesicle invasion) and histopathological characteristics (ISUP grade, percentage of positive biopsy cores, cribriform growth, perineural invasion) using univariable and multivariable logistic regression. Results In multivariable analysis, two independent factors associated with mesorectal lymph node involvement were identified: presence of non-mesorectal lymph node metastases (OR 32.86, CI: 7.10-152.03, p < 0.001) and larger prostate volume (OR 2.00, CI: 1.14–3.51, p = 0.016). Patients with positive MLN uptake had higher prostate specific antigen (PSA) levels (19.60 vs. 8.23 ng/mL, p = 0.02) and more frequent seminal vesicle invasion (44.4% vs. 26.7%, p = 0.04) in univariable analysis, but these associations were not significant in the multivariable model. Conclusion Non-mesorectal lymph node metastases and increased prostate volume are independently associated with mesorectal lymph node involvement in prostate cancer. These findings suggest that careful evaluation of the mesorectal region should be performed in patients with non-mesorectal regional lymph node metastases or larger prostate volumes, potentially impacting treatment planning and radiation field design.
- 27 June 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (1) , 214-222
Factors associated with mesorectal lymph node metastasis in prostate cancer patients
Purpose To evaluate radiological and pathological factors associated with mesorectal lymph node (MLN) metastases in prostate cancer patients, as detected by Prostate Specific Membrane Antigen (PSMA) imaging with Positron Emission Tomography/Computed Tomography (PET/CT). Methods In a retrospective case-control study of 135 prostate cancer patients who underwent PSMA PET/CT between January 2022 and October 2024, forty-five patients with positive mesorectal nodal uptake were matched 1:2 with control patients based on age and International Society of Urological Pathology (ISUP) grade. All patients had multiparametric prostate MR imaging and biopsy results available. We analyzed radiological features (PI-RADS scores, extraprostatic extension, seminal vesicle invasion) and histopathological characteristics (ISUP grade, percentage of positive biopsy cores, cribriform growth, perineural invasion) using univariable and multivariable logistic regression. Results In multivariable analysis, two independent factors associated with mesorectal lymph node involvement were identified: presence of non-mesorectal lymph node metastases (OR 32.86, CI: 7.10-152.03, p < 0.001) and larger prostate volume (OR 2.00, CI: 1.14–3.51, p = 0.016). Patients with positive MLN uptake had higher prostate specific antigen (PSA) levels (19.60 vs. 8.23 ng/mL, p = 0.02) and more frequent seminal vesicle invasion (44.4% vs. 26.7%, p = 0.04) in univariable analysis, but these associations were not significant in the multivariable model. Conclusion Non-mesorectal lymph node metastases and increased prostate volume are independently associated with mesorectal lymph node involvement in prostate cancer. These findings suggest that careful evaluation of the mesorectal region should be performed in patients with non-mesorectal regional lymph node metastases or larger prostate volumes, potentially impacting treatment planning and radiation field design.
- 5 April 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (10) , 4803-4810
SpaceOAR hydrogel complications in prostate cancer radiotherapy: a pictorial review
Since its approval by the United States Food and Drug Administration (FDA), the rectal hydrogel spacer system SpaceOAR (SpaceOAR™ and Space-OAR Vue™, Boston Scientific Corporation, Marlborough, Massachusetts, United States) has become widely adopted in radiation therapy protocols for prostate cancer patients. The biodegradable hydrogel creates a temporary space between the prostate and rectum, thereby effectively reducing the radiation exposure to the anterior rectal wall. While the system is generally safe, potential complications can occur and should be recognized by radiologists. This pictorial review aims to familiarize radiologists with imaging features of SpaceOAR-related complications to ensure accurate diagnosis and reporting.
- 5 April 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (10) , 4803-4810
SpaceOAR hydrogel complications in prostate cancer radiotherapy: a pictorial review
Since its approval by the United States Food and Drug Administration (FDA), the rectal hydrogel spacer system SpaceOAR (SpaceOAR™ and Space-OAR Vue™, Boston Scientific Corporation, Marlborough, Massachusetts, United States) has become widely adopted in radiation therapy protocols for prostate cancer patients. The biodegradable hydrogel creates a temporary space between the prostate and rectum, thereby effectively reducing the radiation exposure to the anterior rectal wall. While the system is generally safe, potential complications can occur and should be recognized by radiologists. This pictorial review aims to familiarize radiologists with imaging features of SpaceOAR-related complications to ensure accurate diagnosis and reporting.
- Open Access
Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer
Purpose: To test the association between the Charlson–Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retrospective data repository of a large university hospital. Kaplan–Meier estimates and uni- and multivariable Cox regression models tested for differences in risk of recurrence according to low vs. high comorbidity burden (CCI ≤ 4 vs. >4) and continuously coded CCI. Results: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6–79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (p = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06–1.92, p = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00–1.10, p = 0.04). Conclusions: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols.
Open AccessCharlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer
Purpose: To test the association between the Charlson–Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retrospective data repository of a large university hospital. Kaplan–Meier estimates and uni- and multivariable Cox regression models tested for differences in risk of recurrence according to low vs. high comorbidity burden (CCI ≤ 4 vs. >4) and continuously coded CCI. Results: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6–79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (p = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06–1.92, p = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00–1.10, p = 0.04). Conclusions: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols.
- Open Access
- 1 June 2022
- Published by Springer Nature in Journal für Urologie und Urogynäkologie/Österreich
- Vol. 29 (2) , 46-53
Update männliche Harnröhrenrekonstruktion
Zusammenfassung: Die Harnröhrenstriktur des Mannes ist eine pathologische Verengung der anterioren Harnröhre und ein häufiges urologisches Krankheitsbild. Sie ist in der westlichen Welt meist iatrogen oder idiopathisch bedingt. Betroffene Patienten geben in der Regel eine bedeutende Einschränkung der Lebensqualität an, welche mittels validierter Fragebögen prä- und postoperativ erhoben werden möchte. Die chirurgische Therapie wird abhängig von Ätiologie, Strikturlokalisation, -länge und -beschaffenheit, Voroperationen sowie individuellen Patientenwünschen gewählt. Die Therapiemöglichkeiten sind vielseitig, teils komplex und sollten allesamt von den behandelnden plastisch-rekonstruktiven ChirurgInnen beherrscht und an spezialisierten Zentren durchgeführt werden. Zu den endourologischen Therapiemöglichkeiten gehören die Harnröhrenbougierung und die Sichturethrotomie. Diese kommen grundsätzlich für einzelne, kurzstreckige primäre bulbäre Harnröhrenstrikturen oder segelförmige Strikturen ohne Spongiofibrose in Frage. Langstreckige, multilokuläre, komplexe, rezidivierende oder penile Harnröhrenstrikturen sollten bei gegebenem gutem Allgemeinzustand des Patienten einer offenen Harnröhrenrekonstruktion unterzogen werden. Zu den offen-chirurgischen Therapien gehören die End-zu-End-Anastomose, die Substitutionsharnröhrenplastik mit einem (Mundschleimhaut‑)Gewebstransplantat und die Rekonstruktion mittels Spalthauttransplantation (Meshgraft) oder als gestielte Lappenplastik. Eine perineale Urethrostomie (Boutonniere) ist eine Alternative für Patienten mit komplexen, vorwiegend penilen Harnröhrenstrikturen und insbesondere für Patienten geeignet, die sich keiner (weiteren) offenen Harnröhrenrekonstruktion unterziehen möchten oder können.
- 1 June 2022
- Published by Springer Nature in Journal für Urologie und Urogynäkologie/Österreich
- Vol. 29 (2) , 46-53
Open AccessUpdate männliche Harnröhrenrekonstruktion
Zusammenfassung: Die Harnröhrenstriktur des Mannes ist eine pathologische Verengung der anterioren Harnröhre und ein häufiges urologisches Krankheitsbild. Sie ist in der westlichen Welt meist iatrogen oder idiopathisch bedingt. Betroffene Patienten geben in der Regel eine bedeutende Einschränkung der Lebensqualität an, welche mittels validierter Fragebögen prä- und postoperativ erhoben werden möchte. Die chirurgische Therapie wird abhängig von Ätiologie, Strikturlokalisation, -länge und -beschaffenheit, Voroperationen sowie individuellen Patientenwünschen gewählt. Die Therapiemöglichkeiten sind vielseitig, teils komplex und sollten allesamt von den behandelnden plastisch-rekonstruktiven ChirurgInnen beherrscht und an spezialisierten Zentren durchgeführt werden. Zu den endourologischen Therapiemöglichkeiten gehören die Harnröhrenbougierung und die Sichturethrotomie. Diese kommen grundsätzlich für einzelne, kurzstreckige primäre bulbäre Harnröhrenstrikturen oder segelförmige Strikturen ohne Spongiofibrose in Frage. Langstreckige, multilokuläre, komplexe, rezidivierende oder penile Harnröhrenstrikturen sollten bei gegebenem gutem Allgemeinzustand des Patienten einer offenen Harnröhrenrekonstruktion unterzogen werden. Zu den offen-chirurgischen Therapien gehören die End-zu-End-Anastomose, die Substitutionsharnröhrenplastik mit einem (Mundschleimhaut‑)Gewebstransplantat und die Rekonstruktion mittels Spalthauttransplantation (Meshgraft) oder als gestielte Lappenplastik. Eine perineale Urethrostomie (Boutonniere) ist eine Alternative für Patienten mit komplexen, vorwiegend penilen Harnröhrenstrikturen und insbesondere für Patienten geeignet, die sich keiner (weiteren) offenen Harnröhrenrekonstruktion unterziehen möchten oder können.